← back to search

Francesco Panzuto

Istituti di Ricovero e Cura a Carattere Scientifico · IT
Area of research
Epidemiology · Oncology
Research interest
Research interests include Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies, Pancreatic and Hepatic Oncology Research, and Neuroblastoma Research and Treatments.
h-index
46
citations
6,556
works
323
NIH funding
primary concept
Medicine
email

Recent publications

The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm.
2026cited by 2position: contributordoi
Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management.
2026cited by 1position: contributordoi
Prognostic value, clinical relevance, and methodological gaps of tumor burden in neuroendocrine tumors (NETs): A systematic review of phase III randomized trials of medical therapies.
2026cited by 0position: contributordoi
Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.
2026cited by 0position: contributordoi
<p class="MDPI12title"><span lang="EN-US" style="mso-bidi-font-size: 18.0pt;">In vivo and In Vitro Efficacy of Statin Therapy in Combination with Somatostatin Analogues in Advanced Bronchopulmonary Neuroendocrine Tumors
2026cited by 0position: contributordoi
AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.
2026cited by 0position: contributordoi
Primary tumor size as a prognostic factor in duodenal neuroendocrine neoplasms ≤20 mm: a population-based SEER analysis.
2026cited by 0position: contributordoi
Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study.
2026cited by 0position: contributordoi
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).
2026cited by 0position: contributordoi
Incidental Gastric Neuroendocrine Tumor on Histology: What Should the Gastroenterologist Do Next?
Gastroenterology Insights 2026cited by 0position: contributordoi
Statins Support the Antitumor Activity of Somatostatin Analogues in Advanced Bronchopulmonary Neuroendocrine Tumors: A Clinical and In Vitro Study
Lipidology 2026cited by 0position: contributordoi
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM).
2025cited by 10position: contributordoi
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries
Endocrine 2025cited by 6position: firstdoi
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries.
2025cited by 6position: contributordoi
The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management.
2025cited by 5position: contributordoi
The efficacy of streptozotocin in managing pancreatic neuroendocrine neoplasms - A systematic review.
2025cited by 5position: contributordoi
Rethinking chromogranin A: unveiling gastrointestinal factors beyond neuroendocrine neoplasms-a narrative review.
2025cited by 4position: contributordoi
Controversies in NEN: An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms.
2025cited by 4position: contributordoi
Nutritional aspects in neuroendocrine neoplasms. bridging the gap between dietary interventions and cancer care strategies: a scoping review.
2025cited by 4position: contributordoi
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients?
2025cited by 3position: contributordoi
Capecitabine and temozolomide or temozolomide alone in patients with atypical carcinoids.
2025cited by 3position: contributordoi
Glucagonoma and Glucagonoma Syndrome: An Updated Review.
2025cited by 3position: contributordoi
Towards a better registration of neuroendocrine neoplasms: The results of the Italian retrospective population-based study.
2025cited by 3position: contributordoi
Controversies in NEN: An ENETS position statement on nutritional support in neuroendocrine neoplasms.
2025cited by 3position: contributordoi
Radiomics in advanced gastroenteropancreatic neuroendocrine neoplasms: Identifying responders to somatostatin analogs.
2025cited by 3position: contributordoi
A Randomized clinical trial evaluating the impact on survival and quality of life of &lt;sup&gt;177&lt;/sup&gt;Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
2025cited by 3position: contributordoi
Impact of dyslipidemia and lipid-lowering therapy with statins in patients with neuroendocrine tumors.
2025cited by 3position: contributordoi
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)
ESMO Open 2025cited by 2position: middledoi
Rectal neuroendocrine tumors: Can we predict their behavior?
2025cited by 2position: contributordoi
A systematic review on endoscopic ultrasound in gastric neuroendocrine neoplasms: guidelines outpacing evidence.
2025cited by 2position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 68 papers (2019–2026)Antongiulio Faggiano · Carlo Forlanini Hospital23 papers (2019–2026)Nicola Fazio · European Institute of Oncology16 papers (2020–2026)Bruno Annibale · Azienda Ospedaliera Sant'Andrea14 papers (2019–2026)Davide Campana · AIAS Bologna14 papers (2019–2026)Gianluca Esposito · Sapienza University of Rome9 papers (2021–2026)Giuseppe Lamberti · Istituto di Nanotecnologia9 papers (2019–2026)Alessandro Zerbi · Humanitas University8 papers (2020–2024)Sara Massironi · Vita-Salute San Raffaele University8 papers (2019–2025)Maria Rinzivillo · Ospedale San Luigi Gonzaga7 papers (2021–2025)Matteo Marasco · Ospedale di Belcolle7 papers (2023–2025)Massimo Falconi · Azienda-Unita' Sanitaria Locale Di Cesena6 papers (2020–2024)Alberto Signore · American Chemical Society6 papers (2019–2022)Damiano Caruso · MDPI6 papers (2022–2025)Roberta Elisa Rossi · Azienda Ospedaliera Universitaria Pisana6 papers (2020–2023)Giulia Arrivi · University of Rome Tor Vergata5 papers (2024–2026)Elisabetta Dell'Unto · Elsevier, Inc.5 papers (2024–2026) · 5 papers (2021–2025)John Ramage · Hampshire Hospitals NHS Foundation Trust4 papers (2020–2023) · 4 papers (2021–2024)